Clinical Trials Logo

Infection clinical trials

View clinical trials related to Infection.

Filter by:

NCT ID: NCT03891433 Recruiting - Clinical trials for Urinary Tract Infections

Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae

CAPITIS
Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

This study evaluates the efficacy in achieving clinical cure in non-bacteremic urinary tract infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae producers of extended-spectrum β-lactamases (ESBL) in adult patients. Half of participants will receive Piperacillin/Tazobactam as treatment, while the other half will receive Carbapenems. The investigators will verify that Piperacillin/Tazobactam is not inferior in achieving clinical cure, and that is not associated with a higher risk of adverse events in the directed treatment of non-bacteremic UTI compared to Carbapenems. The researchers hope to improve the use of antibiotics in the non-bacteremic UTI, reducing the "collateral damage" related to a deterioration in the prognosis of patients and the generation of resistant germs caused by the use of broad-spectrum antibiotics as carbapenems.

NCT ID: NCT03883022 Recruiting - Spinal Stenosis Clinical Trials

Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery

Start date: September 3, 2018
Phase: N/A
Study type: Interventional

Deep surgical site infection (DSSI) is one of the most challenging complications for spinal surgeons and can lead to a poor clinical outcome. This ambispective study was designed to examine the effect of vancomycin powder mixed with autogenous bone graft and bone substitute on preventing deep surgical site infection (DSSI) in degenerative lumbar fusion surgeries as well as any interference with bony fusion.

NCT ID: NCT03865966 Recruiting - Clinical trials for Hepatitis B Infection

Hepatitis B Virus Infection After Liver Transplantation in Children

Start date: July 5, 2019
Phase:
Study type: Observational

China is a highly prevalent area of hepatitis B virus(HBV) infection, with at least 75 million hepatitis B virus carriers, and 80% of primary hepatocellular carcinoma (HCC) is associated with chronic hepatitis B virus infection. Liver transplantation is currently the preferred method for end-stage liver disease such as biliary atresia and cirrhosis in children. In recent years, children's liver transplantation has developed rapidly and the number of developments has increased significantly. If there is chronic hepatitis B virus infection in the donor liver, it may cause HBV transmission, or the patient may have a low-load occult hepatitis B virus infection, and after immunosuppressive treatment, it may lead to hepatitis B virus infection after surgery.

NCT ID: NCT03864952 Recruiting - Infection Clinical Trials

Infectious Agents Exposure : Archiving in Dental Plaque

DIAS
Start date: March 4, 2019
Phase:
Study type: Observational

We are studying the possibility of using dental calculus as a reservoir for the genes of an infectious agent that has infected the patient in previous months; as it is done to highlight climate change in ice samples.

NCT ID: NCT03864263 Recruiting - Clinical trials for Hepatitis b Virus Infection

Hepatitis B Virus Infection in Immunized Children With HBsAg-positive Parents

Start date: July 4, 2019
Phase:
Study type: Observational

Hepatitis B virus (HBV) infection is a major public health problem facing the world, with more than 2 billion people infected with HBV. There are more than 400 million chronic carriers, and 75% of carriers live in the Asia Pacific region. The mother-to-child transmission route of hepatitis B virus is recognized as one of the most important routes of transmission, and recent studies have found that fathers who are carriers of HBV may also be one of the risk factors for HBV infection in children, but as far as the investigators know. Therefore, as a high-population area in China, the purpose of this study is to investigate the prevalence of HBV infection in this population.

NCT ID: NCT03858907 Recruiting - Clinical trials for Cytomegalovirus Infections

Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV

Start date: August 5, 2018
Phase:
Study type: Observational

To evaluate the Quantiferon-CMV test ability to predict occurrence of cytomegalovirus (CMV) disease o treated infection after kidney transplantation. Patients studied are those already infected by CMV before transplantation ("seropositive"). Patients given thymoglobulin as induction therapy receive CMV prophylaxis with valganciclovir, while those given basiliximab undergo weekly monitoring for CMV viremia with preemptive treatment as needed.

NCT ID: NCT03854630 Recruiting - HIV Infections Clinical Trials

Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection

Start date: September 6, 2017
Phase: Phase 4
Study type: Interventional

The primary aim of this open-label, randomized control trial is to compare the immunogenicity at week 28 after 20µg HBV vaccine (at week 0, 4, 24) versus 40µg HBV vaccine (40-µg at week 0, 4, 24 week) among HIV-positive patients or HIV-negative MSM who were born in Taiwan after July 1986 and tested negative for all HBV serological markers. The secondary aims are to assess the safety of double-dose HBV vaccination, the proportions of high-level responders (anti-HBs antibody >100 mIU/ml) at weeks 28 and 48, the serological responses at week 48, and incident HBV infection (indicated by appearance of anti-HBc and/or HBsAg) at week 48.

NCT ID: NCT03846921 Recruiting - Clinical trials for Bacterial Infections

Alpha-defensin as a Diagnostic Means to Distinguish Between Acute Bacterial and Viral Infections

Start date: March 4, 2019
Phase:
Study type: Observational

This study aims to investigate the use of alpha-defensin as a diagnostic means to distinguish between acute bacterial and viral infections.

NCT ID: NCT03844776 Recruiting - Infection Clinical Trials

Preoperative Dose of Co-amoxiclav for Prevention of Postoperative Complications in Dentoalveolar Surgery

Start date: October 2, 2019
Phase: N/A
Study type: Interventional

There was no evidence to judge the effects of preventative antibiotics for extractions of severely decayed teeth, teeth in diseased gums, or extractions in patients who are sick or have low immunity to infection. Undertaking research in these groups of people may not be possible or ethical. However, it is likely that in situations where patients are at a higher risk of infection that preventative antibiotics may be beneficial, because infections in this group are likely to be more frequent and more difficult to treat To the best of knowledge, no adult study has compared the effects of single dose of Co-Amoxiclave and full oral course before or after dentoalveolar surgery. The current study has formally considered this comparison as a potential valuable trail for reducing the postoperative complications in adult patients who have had surgical removal of teeth under LA.

NCT ID: NCT03837990 Recruiting - Clinical trials for Helicobacter Pylori Infection

One Sequencing Find All for Helicobacter Pylori Infection

Start date: May 1, 2019
Phase:
Study type: Observational

The aim of this study is to Identify antibiotic resistance gene mutations in Helicobacter pylori (HP) and genetic diversity of drug metabolism for antibiotics and proton pump inhibitors (PPIs) in patients with HP infection using next-generation sequencing (NGS). The mutation of host/HP strain will be investigated by single NGS, and the eradication results according to genetic polymorphism of host/HP strain will be analyzed.